These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 37641116)

  • 1. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
    Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
    J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
    Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
    Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.
    Hall PE; Schmid P
    Breast Cancer Res Treat; 2022 May; 193(1):21-35. PubMed ID: 35235095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging treatment approaches for triple-negative breast cancer.
    Capuozzo M; Celotto V; Santorsola M; Fabozzi A; Landi L; Ferrara F; Borzacchiello A; Granata V; Sabbatino F; Savarese G; Cascella M; Perri F; Ottaiano A
    Med Oncol; 2023 Dec; 41(1):5. PubMed ID: 38038783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.